AusperBio is a clinical-stage biotechnology company developing AHB-137, an oligonucleotide-based therapy targeting chronic hepatitis B. The company utilizes its Med-Oligo™ ASO platform to create transformative treatments that aim to cure this viral infection and improve patient outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Chronic hepatitis B virus (HBV) infection affects millions globally and can lead to severe liver damage, cirrhosis, and hepatocellular carcinoma. Current treatments often fail to provide a complete cure, requiring long-term management and monitoring. There remains a need for therapies that can effectively suppress HBV replication and achieve sustained viral remission.
Solution
AusperBio is developing AHB-137, an antisense oligonucleotide (ASO) therapy designed to provide a functional cure for chronic HBV infection. AHB-137 leverages the company's Med-Oligo™ ASO platform to target and inhibit the production of HBV viral proteins. By selectively silencing viral gene expression, AHB-137 aims to reduce the viral load, restore immune control, and prevent long-term liver damage. The therapy is currently in clinical trials to evaluate its safety and efficacy in patients with chronic HBV.
Target Audience
The primary target audience includes patients with chronic hepatitis B virus (HBV) infection who are seeking a curative treatment option.
Features
- Med-Oligo™ ASO platform for targeted oligonucleotide drug development
- AHB-137: ASO therapeutic specifically designed to inhibit HBV replication
- Selective silencing of viral gene expression to reduce viral load
- Clinical-stage development with ongoing Phase IIa trials
- Potential for functional cure of chronic HBV infection